Skip to main content
Roche's sBLA for Tecentriq plus chemo accepted for FDA review

Roche Holding's supplemental biologics license application for Tecentriq plus chemotherapy (abraxane and carboplatin) as a first-line therapy for patients with metastatic non-squamous non-small cell lung cancer has been accepted by the FDA for review. The agency has set a PDUFA date of Sept. 2.

Full Story: